Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

Summary

This randomized pilot clinical trial studies atorvastatin calcium in preventing metabolic syndrome in patients with prostate cancer receiving long-term androgen-deprivation therapy. Atorvastatin calcium may help prevent or reduce metabolic syndrome caused by long-term androgen-deprivation therapy

Timeline

Start

2012-03

Primary completion

2013-02

Completion

2013-02

Outcome

Outcome not reported

Stopped: “Other more favorable treatments are now available.”

Drugs

Indications